Skip to main content
Atrás
Watch Compare

Artiva Biotherapeutics, Inc.

Calidad de datos: 100%
ARTV
Nasdaq Manufacturing Chemicals
$6.81
▲ $0.01 (0.15%)
Cap. Mercado: 168.32 M
Precio
$6.81
Cap. Mercado
168.32 M
Rango del Día
—
Rango de 52 Semanas
—
Volumen
—
Apertura —
Promedio 50D / 200D
—
Promedio 50D / 200D
—

Quick Summary

Puntos Clave

Negative free cash flow of -79.34 M

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)-100.00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-60.28%
Below sector avg (-53.53%)
ROIC-47.88%
Net MarginN/A
Op. MarginN/A

Seguridad

Debt / Equity
N/A
Current Ratio11.65
Interest CoverageN/A

Valoración

PE (TTM|NTM)
-2.01 | -2.75
Below sector avg (-1.48)
P/B Ratio1.30
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1366 pares)
Métrica Acción Mediana del Sector
P/E -2.0 -1.5
P/B 1.3 1.6
ROE % -60.3 -53.5
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

Precio Objetivo de Analistas

5 analistas
Buy
Actual
$6.81
+149.6%
Objetivo
$17.00
$10.00
$18.00
$23.00
Pronóstico
P/E Futuro -2.75
EPS Futuro -$2.48
Ingresos Est. 0.0

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2027 -$2.48
-$3.56 – -$1.61
 0.0 3
FY2026 -$3.32
-$4.18 – -$2.25
 0.0 3

Sorpresas de Ganancias

Últimos 4 trimestres
Trimestre EPS Est. EPS Real Sorpresa
Q42025 -$0.80 -$0.84 -5.0%
Q32025 -$0.80 -$0.88 -10.0%
Q22025 -$0.77 -$0.87 -13.0%
Q12025 -$0.62 -$0.83 -33.9%

All Fundamental Metrics
Growth
Revenue Growth (1Y) -100.00% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0.0 Net Income (TTM) -83.87 M
ROE -60.28% ROA -52.70%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -79.34 M
ROIC -47.88% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 11.65
Interest Coverage N/A Asset Turnover 0.00
Working Capital 118.41 M Tangible Book Value 129.22 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2.01 Forward P/E -2.75
P/B Ratio 1.30 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -47.14%
Market Cap 168.32 M Enterprise Value 142.81 M
Per Share
EPS (Diluted TTM) -3.43 Revenue / Share 0.00
FCF / Share -3.21 OCF / Share -3.11
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 94.60%
SBC-Adj. FCF -87.46 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024
Revenue 0.0 251,000.0
Net Income -83.87 M -65.37 M
EPS (Diluted) -3.43 -5.81
Gross Profit — —
Operating Income -89.81 M -67.28 M
EBITDA — —
R&D Expenses 69.54 M 50.33 M
SG&A Expenses — —
D&A 2.60 M 2.43 M
Interest Expense — —
Income Tax 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024
Total Assets 130.94 M 209.58 M
Total Liabilities 20.97 M 22.94 M
Shareholders' Equity 109.97 M 186.64 M
Total Debt — —
Cash & Equivalents 26.70 M 40.24 M
Current Assets 112.67 M 188.63 M
Current Liabilities 13.09 M 12.25 M